Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Phathom Pharmaceuticals (PHAT) over the last 6 years, with Dec 2024 value amounting to $6.2 million.

  • Phathom Pharmaceuticals' Gains from Investment Securities rose 1.79% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year increase of 51.09%. This contributed to the annual value of $6.2 million for FY2024, which is 35.37% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $6.2 million for FY2024, which was up 35.37% from $4.5 million recorded in FY2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Gains from Investment Securities peaked at $6.2 million during FY2024, and registered a low of -$823,000 during FY2021.
  • Its 3-year average for Gains from Investment Securities is $5.4 million, with a median of $5.6 million in 2022.
  • In the last 5 years, Phathom Pharmaceuticals' Gains from Investment Securities plummeted by 154.87% in 2021 and then surged by 778.79% in 2022.
  • Phathom Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $1.5 million in 2020, then plummeted by 154.87% to -$823,000 in 2021, then spiked by 778.79% to $5.6 million in 2022, then declined by 18.58% to $4.5 million in 2023, then soared by 35.37% to $6.2 million in 2024.